See the success of SPIRIVA® in reducing risk of exacerbations
image description

Olivia is successful
in her business.

See the success of SPIRIVA® in reducing her risk of COPD exacerbations

SPIRIVA®: Exacerbation efficacy proven across landmark trials1-3*

POET-COPD®: 1 year trial comparing once-daily SPIRIVA® 18 µg via HandiHaler and twice daily salmeterol 50 µg in time to first exacerbation among 7376 moderate-to-severe COPD patients in 725 centres

SPIRIVA® HandiHaler®
vs salmeterol MDI in GOLD 2-4
moderate-to-severe patients

Study Design
UPLIFT®: 4 year trial comparing once-daily SPIRIVA® 18 µg via HandiHaler and placebo in time to first exacerbation among 5993 moderate-to-severe COPD patients in 490 centres

SPIRIVA® HandiHaler®
vs control in GOLD 2-4
moderate-to-severe patients

Study Design
Bateman 372: 1 year trial comparing once-daily SPIRIVA® Respimat® and placebo in time to first exacerbation and trough FEV1 among 3991 patients in 336 centres

SPIRIVA® Respimat®
vs control in GOLD 2-4
moderate-to-severe patients

Study Design

SPIRIVA® significantly reduced risk and frequency of:

  • COPD exacerbations1,2†‡
  • COPD exacerbations leading to hospitalisations1,3†‡

SPIRIVA®: More than a decade of experience*

  • SPIRIVA® is the most prescribed COPD maintenance treatment worldwide with over 50 million patient-years4,5
  • Unsurpassed long-term, 4-year data in moderate-to-severe exacerbation risk reduction2†‡
  • Efficacy proven across disease severities and regardless of exacerbator risk classification2,6†‡

*Data presented refer to treatment with once-daily SPIRIVA® 18 µg via HandiHaler® or SPIRIVA® Respimat® 2.5 µg (two puffs, once daily).

SPIRIVA® clinical trials include maintenance-naïve patients, patients with GOLD Stage II to IV COPD, and patients with or without concomitant respiratory therapy (including LABA and ICS).

SPIRIVA® did not alter the rate of decline in lung function, a coprimary study endpoint in the UPLIFT® trial.

References
1. Vogelmeier C, Hederer B, Glaab T, et al; for the POET-COPD Investigators. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med. 2011;364(12):1093-1103. 2. Tashkin DP, Celli B, Senn S, et al; for the UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543-1554. 3. Bateman ED, Tashkin D, Siafakas N, et al. A one-year trial of tiotropium Respimat® plus usual therapy in COPD patients. Respir Med. 2010;104(10):1460-1472. 4. Boehringer Ingelheim GmbH, data on file. 5. IMS Health Data, Q4 2015. 6. National Institutes of Health. http://clinicaltrials.gov/ct2/results?term=tiotropium+COPD&Search=Search. Accessed March 23, 2016.